WAVE[®] LIFE SCIENCES

Stereopure AIMers for the treatment of Alpha-1 antitrypsin deficiency (AATD)

Paloma H. Giangrande, PhD VP Platform Discovery Sciences, Biology TIDES US: May 9-12, 2022



Forward looking statements

This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing thereof, competitive position, potential growth opportunities, use of proceeds and the effects of competition are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause the actual results, performance or achievements of Wave Life Sciences Ltd. (the "Company") to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect the Company's business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, including those listed under Risk Factors in the Company's Form 10-K and other filings with the SEC, some of which cannot be predicted or quantified and some of which are beyond the Company's control. The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that the Company may face. Except as required by applicable law, the Company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.



Unlocking RNA editing with PRISM[™] to develop GalNAc-AIMers: A-to-I editing oligonucleotides

Optimize AIMer design for endogenous transcripts and GalNAc conjugation

GalNAc-mediated uptake ASGR Endocytosis Cytoplasm Endosomal Recycling to release cell surface

LIFE SCIENCES


ADAR enzymes

- First publication (1995) using oligonucleotide to edit RNA with endogenous ADAR¹
- Catalyze conversion of A-to-I (G) in doublestranded RNA substrates
- ADAR1 is ubiquitously expressed across tissues, including liver and CNS – sizeable target space
- Cellular reservoir of ADAR capacity supports directed editing in addition to homeostatic function

Optimize AIMer design


- Substrate learnings from biology and structures
- Applied to oligonucleotides
- Applied PRISM chemistry

PRISM-driven gains



¹Woolf et al., 1995 Proc Natl Assoc Sci 92:8298-8302; Monian et al., 2022 Nature Biotech published online Mar 7, 2022 doi: 10.1038.s41587-022-01225-1

Proof-of-concept RNA editing in NHP liver is robust, durable, and specific



WAVE[®] LIFE SCIENCES

AIMer tissue concentration (left) and editing activity (middle) in liver after 5 mg/kg SC injections on days 1-5; Right: Hepatocytes treated with 1 µM AIMer, 48 hrs later RNA collected, RNAseq conducted using strand-specific libraries to quantify editing; plotted circles represent sites with LOD>3. NHP: non-human primate; ACTB: Beta-actin; Monian et al., 2022 published online Mar 7, 2022; doi: 10.1038.s41587-022-01225-1

Proof-of-concept preclinical RNA editing data published in *Nature Biotechnology* (March 2022)

nature	ARTICLES
biotechnology	https://doi.org/10.0038/v41587-022-01225-1
	Check for update

Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides

Prashant Monian12, Chikdu Shivalila12, Genliang Lu1, Mamoru Shimizu1, David Boulay1, Karley Bussow¹, Michael Byrne¹, Adam Bezigian¹, Arindom Chatterjee¹, David Chew¹, Jigar Desai¹, Frank Favaloro¹, Jack Godfrey¹, Andrew Hoss¹, Naoki Iwamoto¹, Tomomi Kawamoto¹, Jayakanthan Kumarasamy', Anthony Lamattina', Amber Lindsey', Fangjun Liu', Richard Looby', Subramanian Marappan¹, Jake Metterville¹, Ronelle Murphy¹, Jeff Rossi¹, Tom Pu¹, Bijay Bhattarai⁰¹, Stephany Standley', Snehlata Tripathi', Hailin Yang', Yuan Yin', Hui Yu', Cong Zhou0', Luciano H. Apponi¹, Pachamuthu Kandasamy¹ and Chandra Vargeese⁰¹⁵⁵

Technologies that recruit and direct the activity of endogenous RNA-editing enzymes to specific cellular RNAs have therapeutic potential, but translating them from cell culture into animal models has been challenging. Here we describe short, chemically modified oligonucleotides called AIMers that direct efficient and specific A-to-1 editing of endogenous transcripts by endog enous adenosine deaminases acting on RNA (ADAR) enzymes, including the ubiquitously and constitutively expressed ADAR p110 isoform. We show that fully chemically modified AlMers with chimeric backbones containing stereopt p 110 isotom. We snow that thay chemically modified and/we's with chimeric backnones containing stereopure prosphoromo-et and nitrogen-containing influences based on hosphoryl guardine enhanced potency and editing efficiency 100-fold com-pared with those with uniformly phosphorothioate-modified backbones in vitro. In vivo, AlMers targeted to hosphorytes the Acadebialactosamine achieve uno 50% editions with no bystander editing of the endogenous ACBB tanscript in non-human primate liver, with editing persisting for at least one month. These results support further investigation of the therapeutic potential of stereopure AlMers.

human disease. The most common mutation in human genes editing in vivo''. is transition from cytosine (C) to thymine (T), and CpG dinucleo-tides are well established hot spots for disease-causian mutations? The ADAR family of enzymes catalyze adenine (A)-to-inosine (I) with high efficiency using endogenous ADAR enzymes. These oligo changes in the transcriptome12. Because L is read as guanine (G) nucleotides called AIMers, are short and fully chemically modified by the translational machinery10, ADAR-mediated RNA editing has with sterecopure phosphorothioate (PS) and nitrogen-containing the potential to revert these disease-causing transitions at the RNA (PN) linkages based on phosphoryl guanidine. In vitro, the level. The potential score for amplication of A.to.I editing is large enhanced potency and A.to.I editing efficiency compared to uni or RNA regulatory sequences⁽¹¹⁾, eliciting diverse functional out-comes (for example, restored protein expression or function)⁽¹⁾. (GalNAc)-modified AIMers achieved up to 50% editing with no bystander editing in non-human primate (NHP) liver that persisted

Chemical modifications are known to confer drug-like proper- for at least 1 month. ties to oligonucleotides. We set out to determine whether control over backbone chemistry and stereochemistry and other chemical Results I) can be optimized to elicit sequence-specific A-to-1 RNA editing. To evaluate RNA-editing efficiency I) can be optimized to elicit sequence-specific A-to-1 RNA editing with endogenous ADAR enzymes. As therapeutics, reversible RNA from Gaussia (Gluc) and Cypridinia (Cluc). In the absence of edit editing with oligonucleotides may represent a safer option than ing, only Gluc is expressed, whereas A-to-I editing permits exprethose that edit genomic DNA'. Early technologies designed to elicit sion of Cluc, providing a measure of RNA-editing efficiency and RNA editing in vitro required an exogenous enzyme and an oligo-protein expression (Extended Data Fig. 1a). AIMers were desig nucleotide 217, These approaches led to overexpression of editing to mimic naturally occurring double-stranded RNA ADAR sul enzyme and substantial off-target editing have overcome the need for exogenous enzymes in vitro³¹⁻²⁰, but they still use long oligonucleotides that require ancillary delivery the still use long oligonucleotides that require ancillary delivery

Cruiting endogenous RNA-editing enzymes using chemi- vehicles, such as viral vectors or lipid nanoparticles, for applicatio cally modified oligonucleotides holds promise for treating beyond cell culture. So far, these technologies have vielded nominal

cluding modulation of polar or charged amino acids, stop codons formly PS-modified AIMers, and in vivo, N-acetylgalactosamine

"Wave Life Sciences, Cambridge, MA, USA "These authors contributed equally. Prashant Monian, Chikdu Shivalila. Re-mail: cvargesce@waveilfesci.com

NATURE BIOTECHNOLOGY I www.sature.com/saturebiotechnolog


- Foundational AIMer SAR •
- GalNAc conjugation •
- In vitro-in vivo translation • (NHPs)
- Specificity in vitro & in vivo (NHPs)



Monian et al., 2022 published online Mar 7, 2022; doi: 10.1038.s41587-022-01225-1 SAR structure-activity relationship

AIMers: Realizing the potential of therapeutic RNA editing by harnessing endogenous ADAR

Solved for key therapeutic attributes for potential best-in-class RNA editing therapeutics




• Strong and broad IP in chemical and backbone modifications, stereochemistry patterns, novel and proprietary nucleosides

¹Shivalila et al., presented at 3rd International Conference on Base Editing – Enzymes and Applications Deaminet 2022

LIFE SCIENCES


SERPINA1 Z mutation: The most common cause of Alpha-1 antitrypsin deficiency (AATD)





Strnad et al., 2020 N Engl J Med 382:1443-55; Stoller et al., 1993 Alpha-1 Antitrypsin Deficiency GeneReviews


SERPINA1 Z mutation: The most common cause of Alpha-1 antitrypsin deficiency (AATD)





RNA editing is uniquely suited to address the therapeutic goals of AATD

Wave ADAR editing approach addresses all treatment goals:



~200K people in US and EU with mutation in SERPINA1 Z allele (PI*ZZ)

WAVE[°]


only lung manifestations

AAT: Alpha-1 antitrypsin Strnad et al., 2020 N Engl J Med 382:1443-55; Blanco et al., 2017 Int J Chron Obstruct Pulmon Dis 12:561-69; Remih et al., 2021 Curr Opin Pharmacol 59:149-56.

Robust SERPINA1 RNA editing in mouse model for AATD restores M-AAT protein in serum

RNA editing in mice day 7 (3x5 mg/kg, SC)








Left: AIMers administered huADAR/SERPINA1 mice (3x5 mg/kg) on days 0, 2, and 4. Livers collected on day 7, and SERPINA1 editing was quantified by Sanger sequencing (shown as mean ± sem) Stats: One-way ANOVA was used to test for differences in editing between SA1-4 and other oligos * P<0.05. Right: huADAR/SERPINA1 mice administered PBS or 3x10 mg/kg AIMer (days 0, 2, and 4) SC. Proportion of AAT protein in serum measured by mass spec, total AAT protein quantified by ELISA.

Bi-weekly AIMer treatment results in serum AAT protein levels in mice above anticipated therapeutic threshold¹

GalNAc-AIMer results in serum AAT protein levels >11 uM at week 19




LIFE SCIENCES

SA1-5 administered in huADAR/SERPINA1 mice (8–10 weeks old) Left: Total serum AAT protein quantified by ELISA. Right: Liver biopsies collected at week 19 (one week after last dose); SERPINA1 editing was quantified by Sanger sequencing; Proportion of AAT protein in serum measured by mass spec, total AAT protein quantified by ELISA ¹Brantly et al., 2018 Chronic Obstr Pulm Dis

Bi-weekly AIMer treatment supports robust RNA editing and M-AAT protein expression in mice

GalNAc-AIMer results in serum AAT protein levels >11 uM

LIFE SCIENCES




SA1-5 administered in huADAR/SERPINA1 mice (8–10 weeks old) Left: Total serum AAT protein quantified by ELISA. Right: Liver biopsies collected at week 19 (one week after last dose); SERPINA1 editing was quantified by Sanger sequencing; Proportion of AAT protein in serum measured by mass spec, total AAT protein quantified by ELISA


Restoration of functional serum M-AAT protein that neutralizes protease activity in mice

Correction of loss-of-function phenotypes

~3-fold in increase in neutrophil elastase inhibition at week 19



Restored M-AAT reaches lungs to protect from proteases







SA1-5 administered in huADAR/SERPINA1 mice (8–10 weeks old); Neutrophil elastase inhibition assay performed with pre-dose and week 19 serum samples, Stats: Mixed effects analysis P<0.001

SA1-5 alleviates aggregation of Z-AAT and inflammation in mouse liver

Correction of gain-of-function phenotypes Z-AAT aggregation causes progressive liver disease



PAS-D staining **PAS-D-positive area** (19 weeks) 15area PBS SA1-5 positive (mean±sem) 10 -%PAS-D Time of treatment (weeks)



LIFE SCIENCES

PBS


SA1-5

SA1-5 administered in huADAR/SERPINA1 mice (8-10 weeks old); lower left: 20x images from liver stained with PAS-D at 19 weeks; Quantification of PAS-D positive staining, Stats 2-way ANOVA; Right: Quantification lobular inflammation grade (Grade based on # of inflammatory foci in lobules: Grade 0: 0: G1 1-5: G2 6-10: G3 11-15: G4 ≥16) and mean globular diameter (40 largest globules per animal) with HALO. Stats Wilcox rank-sum tests

**

AIMer-directed editing is highly specific in mice

No bystander editing observed on SERPINA1 transcript







Dose 3x10 mg/kg (days 0, 2, 4) SC. Liver biopsies day 7. RNA-seq to quantify on-target SERPINA1 editing, to quantify off-target editing reads mapped to entire mouse genome; plotted circles represent sites with LOD>3 (N=4), SERPINA1 edit site is indicated

Opportunity for novel and innovative AIMer therapeutics

Correct driver mutations with AIMers



Restore or correct protein function



Upregulate expression Modify function Modulate protein-protein interaction Post-translational modification Alter folding or processing

Examples AATD

Rett syndrome

Recessive or dominant genetically defined diseases

Examples Haploinsufficient diseases Loss of function Neuromuscular Dementias Familial epilepsies Neuropathic pain



Modulate protein interactions with AIMers

Summary

- Our RNA base editing platform capability allows for correction of the most common causative mutation for AATD in preclinical models
- We have developed RNA editing oligonucleotides AIMers intended to correct homozygous "ZZ" mutations back to "MZ" heterozygous state
- Investigational AIMer leads to durable M-AAT protein levels at or above expected therapeutic threshold
- Restored serum M-AAT inhibits neutrophil elastase, suggesting potential to protect lungs from damage
- Restoration of M-AAT prevents accumulation of Z-AAT aggregates in mouse liver, alleviating phenotypes associated with liver pathology, including inflammation



Acknowledgements



Colleagues and contributors from Wave Life Sciences

(A) Check for updates

Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides

Prashant Monian¹², Chikdu Shivalila¹², Genliang Lu¹, Mamoru Shimizu¹, David Boulav¹, Karley Bussow¹, Michael Byrne¹, Adam Bezigian¹, Arindom Chatterjee¹, David Chew¹, Jigar Desai¹, Frank Favaloro¹, Jack Godfrey¹, Andrew Hoss¹, Naoki Iwamoto¹, Tomomi Kawamoto¹, Jayakanthan Kumarasamy¹, Anthony Lamattina¹, Amber Lindsey¹, Fangjun Liu¹, Richard Looby¹, Subramanian Marappan¹, Jake Metterville¹, Ronelle Murphy¹, Jeff Rossi¹, Tom Pu¹, Bijay Bhattarai^[0], Stephany Standley¹, Snehlata Tripathi¹, Hailin Yang¹, Yuan Yin¹, Hui Yu¹, Cong Zhou¹, Luciano H. Apponi¹, Pachamuthu Kandasamy¹ and Chandra Vargeese¹

Technologies that recruit and direct the activity of endogenous RNA-editing enzymes to specific cellular RNAs have therapeutic potential, but translating them from cell culture into animal models has been challenging. Here we describe short, chemically modified oligonucleotides called AIMers that direct efficient and specific A-to-I editing of endogenous transcripts by endogenous adenosine deaminases acting on RNA (ADAR) enzymes, including the ubiquitously and constitutively expressed ADAR1 p110 isoform. We show that fully chemically modified AlMers with chimeric backbones containing stereopure phosphorothioate and nitrogen-containing linkages based on phosphoryl guanidine enhanced potency and editing efficiency 100-fold compared with those with uniformly phosphorothioate-modified backbones in vitro. In vivo, AlMers targeted to hepatocytes with N-acetylgalactosamine achieve up to 50% editing with no bystander editing of the endogenous ACTB transcript in non-human primate liver, with editing persisting for at least one month. These results support further investigation of the therapeutic potential of stereopure AlMers.

ecruiting endogenous RNA-editing enzymes using chemically modified oligonucleotides holds promise for treating human disease. The most common mutation in human genes is transition from cytosine (C) to thymine (T)1, and CpG dinucleotides are well established hot spots for disease-causing mutations?. The ADAR family of enzymes catalyze adenine (A)-to-inosine (I) changes in the transcriptome¹⁻⁷. Because I is read as guanine (G) by the translational machinery^{8,9}, ADAR-mediated RNA editing has the potential to revert these disease-causing transitions at the RNA (PN) linkages based on phosphoryl guanidine. In vitro, they level. The potential scope for application of A-to-I editing is large, including modulation of polar or charged amino acids, stop codons or RNA regulatory sequences^{10,11}, eliciting diverse functional outcomes (for example, restored protein expression or function)11,

Chemical modifications are known to confer drug-like properties to oligonucleotides. We set out to determine whether control over backbone chemistry and stereochemistry and other chemical modifications to an oligonucleotide (Fig. 1 and Supplementary Note 1) can be optimized to elicit sequence-specific A-to-I RNA editing in mammalian cells, we created a luciferase reporter with genes with endogenous ADAR enzymes. As therapeutics, reversible RNA editing with oligonucleotides may represent a safer option than ing, only Gluc is expressed, whereas A-to-I editing permits expresthose that edit genomic DNA7. Early technologies designed to elicit RNA editing in vitro required an exogenous enzyme and an oligonucleotide¹²⁻¹⁷. These approaches led to overexpression of editing enzyme and substantial off-target editing^{12,14,16-10}, Recent advances strates, as in the GluR2 transcript^{10,13,20} (Extended Data Fig. 1b). have overcome the need for exogenous enzymes in vitro¹¹⁻²⁰, but they still use long oligonucleotides that require ancillary delivery reporter and exogenous ADAR enzyme in the presence or absence

vehicles, such as viral vectors or lipid nanoparticles, for application beyond cell culture7. So far, these technologies have vielded nominal editing in vivo18.

Leveraging our oligonucleotide chemistry platform, we developed relatively short oligonucleotides that elicit A-to-I RNA editing with high efficiency using endogenous ADAR enzymes. These oligonucleotides, called AIMers, are short and fully chemically modified with stereopure phosphorothioate (PS) and nitrogen-containing enhanced potency and A-to-I editing efficiency compared to uniformly PS-modified AIMers, and in vivo, N-acetylgalactosamine (GalNAc)-modified AIMers achieved up to 50% editing with no bystander editing in non-human primate (NHP) liver that persisted for at least 1 month.

Results

AIMers support RNA editing. To evaluate RNA-editing efficiency from Gaussia (Gluc) and Cypridinia (Cluc). In the absence of editsion of Cluc, providing a measure of RNA-editing efficiency and protein expression (Extended Data Fig. 1a). AIMers were designed to mimic naturally occurring double-stranded RNA ADAR sub-

To benchmark RNA editing, we transfected 293T cells with the

1Wave Life Sciences, Cambridge, MA, USA. These authors contributed equally: Prashant Monian, Chikdu Shivalila. Re-mail: cvargeese@wavelifesci.com

NATURE BIOTECHNOLOGY | www.nature.com/naturebiotechnology

